Chordia Therapeutics Inc. is a startup company developing the next generation of anti-cancer drugs based on solid scientific evidence. Our anti-cancer drug pipelines are built around the focus on RNA deregulation, which has been identified as a new hallmark of cancer. Recent studies have newly identified altered RNA regulation in cancer and shown that this RNA deregulation plays a major role in cancer development and progression. Our goal is to develop new therapies that could change the lives of cancer patients by creating small molecule drugs that target RNA deregulation. In order to realize this therapy, it is crucial to have a deep understanding of cancers with RNA deregulation, identify new therapeutic targets, as well as establish a strategy for personalized medicine to deliver new drugs to patients expected to have a significantly higher therapeutic effect. To make this possible, we are actively engaged in joint research with universities and other research institutions that possess next-generation sequencing technology and cutting-edge gene editing technology. Through the above studies, we will explore the potential of Chordia's pipelines to provide beneficial therapeutic effects to cancer patients.